United States Patent	12383512
Kind Code	B2
Date of Patent	August 12, 2025
Inventor(s)	Guy; Geoffrey et al.

Cannabidiol-type cannabinoid compound

Abstract

The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-0 H CBD), is a metabolite of CBD. The cannabinoid can be produced by synthetic means and a method for the production of 6-0 H CBD is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-0 H CBD in a model of disease.

Inventors:	**Guy; Geoffrey (Cambridge, GB), Knappertz; Volker (Cambridge, GB), Whalley; Benjamin (Cambridge, GB), Woolley-Roberts; Marie (Cambridge, GB)**
Applicant:	**Jazz Pharmaceuticals Research UK LImited** (Kent, GB)
Family ID:	**1000008750913**
Assignee:	**JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (Sittingbourne, GB)**
Appl. No.:	**17/777681**
Filed (or PCT Filed):	**November 18, 2020**
PCT No.:	**PCT/GB2020/052942**
PCT Pub. No.:	**WO2021/099781**
PCT Pub. Date:	May 27, 2021

Prior Publication Data

Document Identifier	Publication Date
US 20230000789 A1	Jan. 05, 2023

Foreign Application Priority Data

Publication Classification

Int. Cl.: A61K31/05 (20060101); **A61K36/185** (20060101); **A61P25/08** (20060101)

U.S. Cl.:

CPC **A61K31/05** (20130101); **A61K36/185** (20130101); **A61P25/08** (20180101);

Field of Classification Search

CPC: A61K (31/05); A61K (36/185); A61K (31/658); A61P (25/08); C07C (29/143); C07C (39/23); C07C (2601/16)

References Cited

U.S. PATENT DOCUMENTS

Patent No.	Issued Date	Patentee Name	U.S. Cl.	CPC
6630507	12/2002	Hampson et al.	N/A	N/A
8632825	12/2013	Velasco Diez et al.	N/A	N/A
8790719	12/2013	Parolaro et al.	N/A	N/A
9017737	12/2014	Kikuchi et al.	N/A	N/A
9125859	12/2014	Whalley et al.	N/A	N/A
9474726	12/2015	Guy et al.	N/A	N/A
9949936	12/2017	Guy et al.	N/A	N/A
9949937	12/2017	Guy et al.	N/A	N/A
9956183	12/2017	Guy et al.	N/A	N/A
9956184	12/2017	Guy et al.	N/A	N/A
9956185	12/2017	Guy et al.	N/A	N/A
9956186	12/2017	Guy et al.	N/A	N/A
10092525	12/2017	Guy et al.	N/A	N/A
10111840	12/2017	Guy et al.	N/A	N/A
10137095	12/2017	Guy et al.	N/A	N/A
10583096	12/2019	Guy et al.	N/A	N/A
10603288	12/2019	Guy et al.	N/A	N/A
10709671	12/2019	Guy et al.	N/A	N/A
10709673	12/2019	Guy	N/A	N/A
10709674	12/2019	Guy et al.	N/A	N/A
10765643	12/2019	Guy et al.	N/A	N/A
10807777	12/2019	Whittle	N/A	N/A
10849860	12/2019	Guy et al.	N/A	N/A
10918608	12/2020	Guy et al.	N/A	N/A
10966939	12/2020	Guy et al.	N/A	N/A
11065209	12/2020	Guy et al.	N/A	N/A
11065227	12/2020	Stott et al.	N/A	N/A
11096905	12/2020	Guy et al.	N/A	N/A
11147776	12/2020	Stott et al.	N/A	N/A
11147783	12/2020	Stott et al.	N/A	N/A

11154516	12/2020	Guy et al.	N/A	N/A
11154517	12/2020	Guy et al.	N/A	N/A
11160757	12/2020	Wilkhu et al.	N/A	N/A
11160795	12/2020	Guy et al.	N/A	N/A
11207292	12/2020	Guy et al.	N/A	N/A
11229612	12/2021	Wright et al.	N/A	N/A
11291631	12/2021	Shah	N/A	N/A
11311498	12/2021	Guy et al.	N/A	N/A
11357741	12/2021	Guy et al.	N/A	N/A
11400055	12/2021	Guy et al.	N/A	N/A
11406623	12/2021	Guy et al.	N/A	N/A
11419829	12/2021	Whalley et al.	N/A	N/A
11426362	12/2021	Wright et al.	N/A	N/A
11446258	12/2021	Guy et al.	N/A	N/A
11590087	12/2022	Guy et al.	N/A	N/A
11633369	12/2022	Guy et al.	N/A	N/A
11679087	12/2022	Guy et al.	N/A	N/A
11684598	12/2022	Stott et al.	N/A	N/A
11701330	12/2022	Guy et al.	N/A	N/A
11766411	12/2022	Guy et al.	N/A	N/A
11793770	12/2022	Stott et al.	N/A	N/A
11806319	12/2022	Wilkhu et al.	N/A	N/A
11865102	12/2023	Guy et al.	N/A	N/A
11963937	12/2023	Guy	N/A	N/A
12023305	12/2023	Whalley et al.	N/A	N/A
12064398	12/2023	Wright et al.	N/A	N/A
12064399	12/2023	Guy et al.	N/A	N/A
12102619	12/2023	Guy et al.	N/A	N/A
2014/0298511	12/2013	Lewis et al.	N/A	N/A
2015/0359756	12/2014	Guy et al.	N/A	N/A
2017/0239193	12/2016	Guy et al.	N/A	N/A
2018/0071210	12/2017	Wilkhu et al.	N/A	N/A
2018/0228751	12/2017	Stott et al.	N/A	N/A
2019/0167583	12/2018	Shah	N/A	N/A
2019/0314296	12/2018	Wright et al.	N/A	N/A
2019/0321307	12/2018	Guy et al.	N/A	N/A
2019/0365667	12/2018	Wright et al.	N/A	N/A
2020/0138738	12/2019	Guy et al.	N/A	N/A
2020/0179303	12/2019	Guy et al.	N/A	N/A
2020/0206153	12/2019	Whalley et al.	N/A	N/A
2020/0237683	12/2019	Whalley et al.	N/A	N/A
2020/0297656	12/2019	Guy et al.	N/A	N/A
2020/0352878	12/2019	Guy et al.	N/A	N/A
2021/0015789	12/2020	Guy et al.	N/A	N/A
2021/0052512	12/2020	Guy et al.	N/A	N/A
2021/0059949	12/2020	Wilkhu et al.	N/A	N/A
2021/0059960	12/2020	Wilkhu et al.	N/A	N/A
2021/0059976	12/2020	Wilkhu et al.	N/A	N/A
2021/0169824	12/2020	Guy et al.	N/A	N/A
2021/0177773	12/2020	Guy et al.	N/A	N/A

2021/0290565	12/2020	Guy et al.	N/A	N/A
2021/0330636	12/2020	Guy et al.	N/A	N/A
2021/0401771	12/2020	Guy et al.	N/A	N/A
2022/0000800	12/2021	Guy et al.	N/A	N/A
2022/0008355	12/2021	Guy et al.	N/A	N/A
2022/0016048	12/2021	Guy et al.	N/A	N/A
2022/0023232	12/2021	Guy et al.	N/A	N/A
2022/0040155	12/2021	Guy et al.	N/A	N/A
2022/0062197	12/2021	Stott et al.	N/A	N/A
2022/0062211	12/2021	Stott et al.	N/A	N/A
2022/0087951	12/2021	Knappertz	N/A	N/A
2022/0096397	12/2021	Wright et al.	N/A	N/A
2022/0168266	12/2021	Guy et al.	N/A	N/A
2022/0183997	12/2021	Guy et al.	N/A	N/A
2022/0184000	12/2021	Guy et al.	N/A	N/A
2022/0202738	12/2021	Guy et al.	N/A	N/A
2022/0211629	12/2021	Wilkhu et al.	N/A	N/A
2022/0226257	12/2021	Guy et al.	N/A	N/A
2022/0249396	12/2021	Guy et al.	N/A	N/A
2022/0257529	12/2021	Guy et al.	N/A	N/A
2022/0265573	12/2021	Guy et al.	N/A	N/A
2022/0288055	12/2021	Silcock et al.	N/A	N/A
2022/0378714	12/2021	Guy et al.	N/A	N/A
2022/0395471	12/2021	Guy et al.	N/A	N/A
2023/0022487	12/2022	Guy et al.	N/A	N/A
2023/0024312	12/2022	Whalley et al.	N/A	N/A
2023/0026079	12/2022	Guy et al.	N/A	N/A
2023/0032502	12/2022	Guy et al.	N/A	N/A
2023/0038423	12/2022	Silcock et al.	N/A	N/A
2023/0068885	12/2022	Guy et al.	N/A	N/A
2023/0143812	12/2022	Knappertz et al.	N/A	N/A
2023/0235825	12/2022	Thompson et al.	N/A	N/A
2023/0248664	12/2022	Guy	N/A	N/A
2023/0263744	12/2022	Guy et al.	N/A	N/A
2023/0277560	12/2022	Checketts et al.	N/A	N/A
2023/0277561	12/2022	Checketts et al.	N/A	N/A
2023/0277562	12/2022	Checketts et al.	N/A	N/A
2023/0277563	12/2022	Checketts et al.	N/A	N/A
2023/0285419	12/2022	Checketts et al.	N/A	N/A
2023/0285420	12/2022	Checketts et al.	N/A	N/A
2023/0285421	12/2022	Checketts et al.	N/A	N/A
2023/0285422	12/2022	Checketts et al.	N/A	N/A
2023/0285423	12/2022	Checketts et al.	N/A	N/A
2023/0285424	12/2022	Checketts et al.	N/A	N/A
2023/0285425	12/2022	Checketts et al.	N/A	N/A
2023/0285426	12/2022	Checketts et al.	N/A	N/A
2023/0285427	12/2022	Checketts et al.	N/A	N/A
2023/0285428	12/2022	Checketts et al.	N/A	N/A
2023/0301934	12/2022	Whalley et al.	N/A	N/A
2023/0301936	12/2022	Guy et al.	N/A	N/A

2023/0310464	12/2022	Checketts et al.	N/A	N/A
2023/0346809	12/2022	Craig	N/A	N/A
2023/0372367	12/2022	Checketts et al.	N/A	N/A
2023/0372368	12/2022	Checketts et al.	N/A	N/A
2024/0016819	12/2023	Craig	N/A	N/A
2024/0025858	12/2023	Silcock et al.	N/A	N/A
2024/0033229	12/2023	Guy et al.	N/A	N/A
2024/0033272	12/2023	Checketts et al.	N/A	N/A
2024/0043388	12/2023	Silcock et al.	N/A	N/A
2024/0050452	12/2023	Craig et al.	N/A	N/A
2024/0091241	12/2023	Guy et al.	N/A	N/A
2024/0130981	12/2023	Wilkhu	N/A	N/A
2024/0131041	12/2023	Tse	N/A	N/A
2024/0165048	12/2023	Guy	N/A	N/A
2024/0207220	12/2023	Guy et al.	N/A	N/A
2024/0215910	12/2023	Tse et al.	N/A	N/A
2024/0226032	12/2023	Wilkhu et al.	N/A	N/A
2024/0226123	12/2023	Tse	N/A	N/A
2024/0238218	12/2023	Silcock et al.	N/A	N/A
2024/0254066	12/2023	Silcock et al.	N/A	N/A
2024/0254072	12/2023	Silcock et al.	N/A	N/A
2024/0261234	12/2023	Guy	N/A	N/A
2024/0293762	12/2023	Loft et al.	N/A	N/A

FOREIGN PATENT DOCUMENTS

Patent No.	Application Date	Country	CPC
WO-2015193667	12/2014	WO	N/A
WO-2015193668	12/2014	WO	N/A
WO-2016094810	12/2015	WO	N/A
WO-2016203239	12/2015	WO	N/A
WO-2018061007	12/2017	WO	N/A
WO-2018205022	12/2017	WO	N/A

OTHER PUBLICATIONS

Harvey, D. J., "Characterization of the Butyl Homologues of Delta1-tetrahydrocannabinol, Cannabinol and Cannabidiol in Samples of Cannabis by Combined Gas Chromatography and Mass Spectrometry," J. Pharm. Pharmac., 28:280-285 (1976). cited by applicant

Hill, T. D. M. et al., "Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB 1 receptor-independent mechanism," British Journal of Pharmacology, 170(3):679-692 (2013). cited by applicant

Morales, P. et al., "An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol," Frontiers in Pharmacology, 8:422 (2017); doi:10.3389/fphar.2017.00422, 18 pages. cited by applicant

Epidiolex® (cannabidiol) oral solution, CV, Prescribing Information, 2018, 30 pages; https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf. cited by applicant

Gaston, T. E. & Szaflarski, J. P., "Cannabis for the Treatment of Epilepsy: an Update," Current Neurology and Neuroscience Reports, 18:73 (2018); doi:10.1007/s11910-018-0882-y. cited by applicant

Kimball, A. W. et al., Chemical Protection against Ionizing Radiation, Radiation Research, 7:1-12 (1957). cited by applicant

Lander, N. et al., "Total Syntheses of Cannabidiol and A1-Tetrahydrocannabiinol Metabolites," J Chem Soc Perkin 1, (1):8-16 (1976). cited by applicant

Lewis, M. M. et al., Chemical Profiling of Medical Cannabis Extracts, ACS Omega, 2:6091-6103 (2017). cited by applicant

Litchfield, J. T. & Wilcoxon, F., A simplified method of evaluating dose-effect experiments, J Pharmacol Exp Ther, 96(2):99-113 (1949). cited by applicant

Loscher, W. et al., The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models, Epilepsy Res., 8:79-94 (1991). cited by applicant

Pertwee, R. G., "The Pharmacology and Therapeutic Potential of Cannabidiol," Cannabinoids, Chapter 3, DiMarzo, V. (Ed.), pp. 32-83 (2004). cited by applicant

Swinyard, E. A. & Kupferberg, H. J., "Antiepileptic drugs: detection, quantification, and evaluation," Federation Proceedings, 44(10):2629-2633 (1985). cited by applicant

Ujávry, I. & Hanus, L., "Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy," Cannabis and Cannabinoid Research, 1(1):90-101 (2016); doi:10.1089/can.2015.0012. cited by applicant

Primary Examiner: Javanmard; Sahar

Attorney, Agent or Firm: COOLEY LLP

Background/Summary

FIELD OF THE INVENTION
(1) The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament.
(2) The CBD-type cannabinoid, 6-hydroxy cannabidiol (6-OH CBD), is a metabolite of CBD.
(3) The cannabinoid can be produced by synthetic means.
(4) Disclosed herein are data which demonstrate the efficacy of 6-OH CBD in a model of disease. In addition, a method for the production of 6-OH CBD is described.
BACKGROUND TO THE INVENTION
(5) Cannabinoids are natural and synthetic compounds structurally or pharmacologically related to the constituents of the cannabis plant or to the endogenous agonists (endocannabinoids) of the cannabinoid receptors CB1 or CB2. The only way in nature in which these compounds are produced is by the cannabis plant. *Cannabis* is a genus of flowering plants in the family Cannabaceae, comprising the species *Cannabis sativa, Cannabis indica,* and *Cannabis ruderalis* (sometimes considered as part of *Cannabis sativa*).
(6) *Cannabis* plants comprise a highly complex mixture of compounds. At least 568 unique molecules have been identified. Among these compounds are cannabinoids, terpenoids, sugars, fatty acids, flavonoids, other hydrocarbons, nitrogenous compounds, and amino acids.
(7) Cannabinoids exert their physiological effects through a variety of receptors including, but not limited to, adrenergic receptors, cannabinoid receptors (CB1 and CB2), GPR55, GPR3, or GPR5. The principle cannabinoids present in *Cannabis* plants are cannabinoid acids Δ9-tetrahydrocannabinolic acid (Δ9-THCA) and cannabidiolic acid (CBDA) with small amounts of their respective neutral (decarboxylated) cannabinoids. In addition, *Cannabis* may contain lower levels of other minor cannabinoids. "Chemical composition, pharmacological profiling, and complete physiological effects of these medicinal plants, and more importantly the extracts from *Cannabis*, remain to be fully understood." Lewis, M. M. et al., ACS Omega, 2, 6091-6103 (2017).

(8) Crude extracts from *Cannabis* plants containing CBD have been used by patients suffering from diseases and disorders. However, such crude products are unsuitable for use in pharmaceutical formulations. Those seeking to prepare more consistent CBD preparations for use in treating diseases or disorders have made a concerted effort to either prepare CBD synthetically or attempt to remove all compounds other than CBD, particularly psychoactive compounds such as THC, from plant derived cannabinoids. See for example US 2014/0298511.

(9) The present invention encompasses the surprising discovery that a metabolite of CBD has therapeutic efficacy. This compound, 6-hydroxy cannabidiol (6-OH CBD) can be produced synthetically and may be used in a purified form.

(10) Cannabinoids are a class of compounds which many of which can be derived naturally from the cannabis plant or produced synthetically via chemical synthesis.

(11) More than 100 different cannabinoids produced by *Cannabis* have been identified. These cannabinoids can be split into different groups as follows: phytocannabinoids; endocannabinoids and synthetic cannabinoids (which may be novel cannabinoids or synthetically produced versions of phytocannabinoids or endocannabinoids).

(12) Phytocannabinoids are cannabinoids that originate from nature and can be found in the *Cannabis* plant. Phytocannabinoids can be isolated from plants to produce a highly purified extract. Phytocannabinoids may be obtained as either the neutral (decarboxylated form) or the carboxylic acid form depending on the method used to extract the cannabinoids from plant material. For example, it is known that heating the carboxylic acid form will cause most of the carboxylic acid form to decarboxylate into the neutral form. Phytocannabinoids can only be produced from plants, however versions of phytocannabinoids may be produced synthetically via chemical synthesis.

(13) Endocannabinoids are endogenous lipid-based retrograde neurotransmitters that bind to cannabinoid receptors, and cannabinoid receptor proteins that are expressed throughout the mammalian central nervous system (including the brain) and peripheral nervous system. The endocannabinoid system is involved in regulating a variety of physiological and cognitive processes including fertility, pregnancy, during pre- and postnatal development, appetite, pain-sensation, mood, and memory, and in mediating the pharmacological effects of *Cannabis*.

(14) Synthetic cannabinoids are compounds that have a cannabinoid-like structure and are manufactured using chemical means rather than by the plant.

(15) Certain cannabinoids are described in more detail below.

(16) Cannabidiol (CBD) is a major cannabinoid constituent of *Cannabis* species, such as the hemp plant (*Cannabis sativa*). Unlike other cannabinoids, such as THC, cannabidiol does not bind CB1 or CB2, or its binding to the receptors is negligible in terms of inducing a pharmacological effect. Thus, cannabidiol does not cause the central or peripheral nervous system effects mediated by the CB1 or CB2 receptors. CBD has little or no psychotropic (cannabimimetic) activity and its molecular structure and properties are substantially different from those of other cannabinoids.

(17) Cannabidiol administration has been the subject of research in an attempt to provide an alternative treatment for various diseases and disorders which may respond to such treatment.

(18) There have been many studies done in animals to determine the metabolism of CBD. The pharmacokinetics of CBD are complex, mainly due to a substantial first pass effect. This in turn causes the bioavailability of oral CBD to be poor in humans and other species.

(19) The most abundant metabolites of CBD are hydroxylated 7-carboxy derivatives of CBD which include: 2″-OH-7-COOOH,3″,4″,5″-trinor CBD; CBD-glucuronide; 4″-OH-7-COOH CBD; 2″-OH-7-COOH CBD; 10-OH-7-COOH CBD; 3″-OH-7-COOH CBD; 7-OH-3″-COOH,4″,5″-dinor CBD; 7-COOH-8,9-dihydro-8,9-diOH CBD; 1″-OH-7-COOH CBD; 6-OH-42-COOH,5″-nor CBD; 6-OH-3″-COOH,4″,5″-dinor CBD; 7-COOH CBD; 7-OH-4″-COOH,5″-nor CBD; 4″-COOH,5″-nor CBD; 7-OH CBD; 8,9-dihydro-7,8,9-triOH CBD; cannabinol; 3″-COOH,4″,5″-dinor CBD; 2″-COOH,3″,4″,5″-trinor CBD; 2″,6-diOH,3″,4″,5″-trinor CBD6,7-diOH CBD; 7-OH-1″-COOH,2″,3″,4″,5″-tetranor CBD; 6-OH CBD; 7-OH-5″-COOH CBD; 1″-COOH,2″,3″,4″,5″-

tetranor CBD; 6-OH-1″-COOH,2″,3″,4″,5″-tetranor CBD and 6-OH-5″-COOH CBD (Ujvary and Hanus, 2016).

(20) The U.S. Pat. No. 6,630,507 describes numerous analogues of cannabidiol. The compound 6-OH CBD is detailed in the document however there are no data presented to provide evidence that this compound may have any efficacy as a therapeutic agent.

(21) Tetrahydrocannabinol (THC) is the principal psychoactive constituent of cannabis. THC is a partial agonist at the CB1 and CB2 receptors. Synthetic THC or dronabinol is approved for the treatment of loss of appetite in AIDS patients and nausea and vomiting caused by cancer chemotherapy.

(22) Of the over 100 natural cannabinoids identified in *Cannabis sativa*, seven have been classified as CBD-type compounds, these cannabinoids have the same absolute configuration as CBD. These are: CBD, Cannabidiolic acid (CBDA), Cannabidivarin (CBDV), Cannabidivarin acid (CBDVA), Cannabidiol-C1 (CBD-C1), Cannabidiol-C4 (CBD-C4), Cannabidiol-C6 (CBD-C6) and Cannabidiol monomethyl ether (CBDM).

(23) Cannabidiolic acid (CBDA) is the main form in which CBD exists in the cannabis plant. It is converted into CBD after decarboxylation.

(24) Cannabidivarin (CBDV) is a homolog of CBD, with the sidechain shortened by two methylene bridges. CBDV is a non-psychoactive cannabinoid and has been shown to have anti-convulsant activity in a mouse model of epilepsy.

(25) Cannabidiol-C1 (CBD-C1) also known as cannabidiorcol is a homolog of CBD, with the sidechain shortened by four methylene bridges. CBD-C1 occurs naturally in plants producing CBD but has not been shown to have any therapeutic effects.

(26) Cannabidiol-C4 (CBD-C4) also known as nor-cannabidiol is a homolog of CBD, with the sidechain shortened by one methylene bridge. CBD-C4 occurs naturally in plants producing CBD and prior to the present invention has not been shown to have any therapeutic effects.

(27) Cannabidiol-C6 (CBD-C6) is a homolog of CBD, with the sidechain increased by one methylene bridge. CBD-C6 may occur naturally in plants producing CBD and prior to the present invention has not been shown to have any therapeutic effects.

(28) The present invention demonstrates data for the first time to indicate that the compound 6-hydroxy cannabidiol may have therapeutic benefit.

BRIEF SUMMARY OF THE DISCLOSURE

(29) In accordance with a first aspect of the present invention there is provided 6-hydroxy cannabidiol (6-OH CBD) for use as a medicament.

(30) Preferably the 6-OH CBD is present as a synthetic compound. Alternatively, the 6-OH CBD is present as a pure and isolated compound.

(31) Preferably the dose of 6-OH CBD is greater than 100 mg/kg/day. More preferably the dose of 6-OH CBD is greater than 250 mg/kg/day. More preferably the dose of 6-OH CBD is greater than 500 mg/kg/day. More preferably the dose of 6-OH CBD is greater than 750 mg/kg/day. More preferably the dose of 6-OH CBD is greater than 1000 mg/kg/day. More preferably the dose of 6-OH CBD is greater than 1500 mg/kg/day.

(32) Alternatively, the dose of 6-OH CBD is less than 100 mg/kg/day. More preferably the dose of 6-OH CBD is less than 50 mg/kg/day. More preferably the dose of 6-OH CBD is less than 20 mg/kg/day. More preferably the dose of 6-OH CBD is less than 10 mg/kg/day. More preferably the dose of 6-OH CBD is less than 5 mg/kg/day. More preferably the dose of 6-OH CBD is less than 1 mg/kg/day. More preferably the dose of 6-OH CBD is less than 0.5 mg/kg/day.

(33) In accordance with a second aspect of the present invention there is provided a composition for use as a medicament comprising 6-hydroxy cannabidiol (6-OH CBD), and one or more pharmaceutically acceptable excipients.

(34) In accordance with a third aspect of the present invention there is provided a 6-hydroxy cannabidiol (6-OH CBD) for use in the treatment of epilepsy. Preferably the epilepsy is treated in a

mammal. More preferably the mammal is a human. Alternatively, the mammal is a dog.

(35) In accordance with a fourth aspect of the present invention there is provided a method for the production of 6-hydroxy cannabidiol.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) Embodiments of the invention are further described hereinafter with reference to the accompanying drawings, in which:

(2) FIG. **1** shows the effect of 6-OH CBD in the MEST test in mouse.

(3) FIG. **2** shows the pharmacokinetics of 6-OH CBD in plasma and brain of mice following a single intravenous or intraperitoneal administration.

Cannabinoids And Their Abbreviations

(4) The cannabinoids described in the present application are listed below along with their standard abbreviations.

(5) TABLE-US-00001 CBD Cannabidiol embedded image 6-OH CBD Alpha 6-hydroxy cannabidiol embedded image

DETAILED DESCRIPTION

Example 1: Synthetic Production Method for Alpha 6-Hydroxy Cannabidiol (6-OH CBD)

(6) The compound 6-OH CBD is a known metabolite of cannabidiol.

(7) The synthetic pathway described below details a methodology that can be used in order to produce the cannabinoid alpha 6-OH CBD.

(8) On the scheme R=C.sub.5H.sub.11

(9) To cannabidiol (5.00 g, 15.8 mmol) in anhydrous pyridine (20 mL) was added acetic anhydride (5.13 g, 4.75 mL, 50.2 mmol) and the solution was stirred for 4 h. Dichloromethane (300 mL) was added and the solution was washed with water (200 ml), 1M hydrochloric acid (200 mL), saturated aqueous sodium bicarbonate (200 mL), dried (MgSO4) and concentrated to give cannabidiol diacetate (5.72 g, quantitative), as a straw yellow oil which was used without further purification.

(10) To cannabidiol diacetate (6.18 g, 15.5 mmol) in glacial acetic acid (14 mL) and acetic anhydride (7.12 g, 6.59 mL, 69.8 mmol) was added sodium dichromate (4.87 g, 18.6 mmol) and the mixture was stirred at room temperature for 4 days. The resulting solution was diluted with water (200 mL) and extracted with diethyl ether (200 mL followed by 150 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate (2×100 mL), dried (MgSO4) and concentrated to give a yellow oil that was purified using a Biotage Isolera automated chromatography system under normal phase conditions (silica column, gradient of 5.fwdarw.32% ethyl acetate in petrol) with detection at 254 nm to give 6-oxo-cannabidiol diacetate (2.03 g 33%), as a colourless oil.

Rf=0.45 (ethyl acetate-petrol, 1:4 v/v)

(11) To lithium aluminium hydride (355 mg, 9.37 mmol) in diethyl ether (36 mL) at 0° C. was added 6-oxo-cannabidiol diacetate (0.92 g, 2.23 mmol) in diethyl ether (8 mL) and the mixture was stirred at room temperature for 4 h. The resulting mixture was cooled in an ice bath and cautiously quenched with water (10 mL) dropwise. 1 M Hydrochloric acid (60 mL) was added and the mixture was extracted with diethyl ether (100 mL). The organic layer was washed with saturated brine (80 mL), dried (MgSO4) and concentrated to give a pale yellow oil that was purified using a Biotage Isolera automated chromatography system under normal phase conditions (silica column, gradient of 7.fwdarw.47% ethyl acetate in petrol) with detection at 254 nm to afford 6-oxo-cannabidiol (0.51 g, 69%), as a white glassy solid.

(12) Rf=0.34 (ethyl acetate-petrol, 3:7 v/v)

(13) ##STR00003##

(14) The resultant material was confirmed to be alpha 6-hydroxy-cannabidiol (6-OH CBD). The compound is a yellow glassy semi-solid material with the chemical formula $C_{21}H_{30}O_3$ and a molecular weight of 330.5 g/mol.

(15) Purity of the compound was tested by HPLC which was shown to produce a 95.6% pure material.

(16) 6-OH CBD was stored at −20° C. and protected from light until required for testing.

Example 2: Evaluation of 6-Hydroxy CannabidioL (6-OH CBD) for Anticonvulsant Activity Using the Supramaximal Electroshock Seizure (MES) Test in the Mouse

(17) The efficacy of 6-OH CBD was tested in a mouse model of seizure, the supramaximal electroshock seizure (MES) test.

(18) The supramaximal electroshock seizure (MES) test is widely utilized preclinically to evaluate anti-convulsant properties of molecules and standard anti-epileptic drugs (Loscher et al., 1991).

(19) The MES test is a very stringent model in which mice receive a predetermined high-level electrical stimulus of sufficient intensity to reliably produce tonic hindlimb extensor seizures in 100% of control animals. As such the MES test is a rigorous evaluation of anticonvulsant activity (Swinyard, 1985).

Methods

(20) Naïve mice were acclimatised to the procedure room in their home cages, with food and water available ad libitum.

(21) Animals were dosed i.p. according to treatment group.

(22) The vehicle (10 ml/kg i.p. 60 min pre-treatment time) was 1:1:18 vehicle 5% ethanol, 5% kolliphor EL, 90% saline.

(23) The test compound, alpha 6-OH CBD was prepared according to the method described in Example 1.

(24) The test compound, 6-OH CBD was administered at doses of 3, 30, 100 and 200 mg/kg given at 10 ml/kg i.p. 60 min pre-treatment time.

(25) In addition, a dose of 100 mg/kg CBD was given at 10 ml/kg i.p. at 120 minutes pre-treatment time to assess the effect of the drug over a longer time course.

(26) The positive control valproate was used at 250 mg/kg (10 ml/kg i.p. 30 min pre-treatment time).

(27) Mice were individually assessed for the production of a tonic hind limb extensor seizure following a pre-determined high level (30 mA: 50 Hz) corneally delivered electroshock (0.2 sec duration) of sufficient intensity to reliably produce tonic hindlimb seizures in 100% of control animals.

(28) Induction of seizure is measured as an all-or-nothing effect scored as either present (+) or absent (0) for each animal.

(29) Data was collected by an observer unaware of the treatment for each animal and was expressed as the number of +'s or 0's for each treatment group.

(30) The percentage inhibition of relevant vehicle treated group (the protection relative to vehicle treated controls) was then generated.

(31) Significant differences between individual treatment groups and vehicle-treated groups were assessed using 2-tailed Fisher's Exact Probability test ($p < 0.05$ considered significant).

Results

(32) Table 1 below demonstrates the data produced in this experiment.

(33) In the positive control valproate (250 mg/kg) treated group, administered i.p. 30 minutes before the test, all animals were scored as not having a seizure. This result was statistically significant ($p < 0.001$) compared to the vehicle control.

(34) In the 6-OH CBD treatment groups, administered i.p. 120 minutes before the test, the dose of 3 mg/kg 6-OH CBD was ineffective. However, the doses of 30, 100 and 200 mg/kg 6-OH CBD enabled all mice within the group to withstand seizures and produced a statistically significant

effect compared to vehicle (p<0.001).

(35) In addition, the dose of 6-OH CBD (100 mg/kg) given 120 minutes also produced a statistically significant reduction of seizures compared to the vehicle control.

(36) TABLE-US-00002 TABLE 1 Evaluation of effect of 6-OH CBD in the MES test

Treatment	Dose (mg/kg)	N	Pre-treatment time (mins)	% change from vehicle	Significance Vehicle
Vehicle	—	10	60	—	—
Valproate	250	10	30	100%	P < 0.001
6-OH CBD	3	10	60	0%	—
6-OH CBD	30	10	60	100%	P < 0.001
6-OH CBD	100	10	60	100%	P < 0.001
6-OH CBD	200	10	60	100%	P < 0.001
6-OH CBD	100	10	120	100%	P < 0.001

Conclusions

(37) These data demonstrate for the first time a therapeutic effect for the compound 6-OH CBD.

(38) The data showing the 6-OH CBD given 2 hours (120 minutes) before the mice received the electroshock demonstrates that the compound was able to have a long-lasting effect.

(39) These data are significant as they provide heretofore unknown evidence that this cannabinoid may be of therapeutic value.

Example 3: Evaluation of 6-Hydroxy Cannabidiol (6-OH CBD) for Anticonvulsant Activity Using the Maximal Electroshock Seizure Threshold (MEST) Test in the Mouse

(40) The efficacy of 6-OH CBD was tested in a mouse model of generalised seizure, the maximal electroshock seizure threshold (MEST) test.

(41) The maximal electroshock seizure threshold (MEST) test is widely utilized preclinically to evaluate pro- or anti-convulsant properties of test compounds (Loscher et al., 1991).

(42) In the MEST test the ability of a drug to alter the seizure threshold current required to induce hind limb tonic extensor convulsions is measured according to an "up and down" method of shock titration (Kimball et al., 1957). An increase in seizure threshold is indicative of anti-convulsant effect. Antiepileptic drugs including the sodium channel blockers (e.g. lamotrigine) with clinically proven efficacy against generalised tonic-clonic seizures all exhibit anti-convulsant properties in this test in the mouse.

(43) Conversely, a reduction in seizure threshold is indicative of a pro-convulsant effect as observed with known convulsant agents such as picrotoxin.

(44) The ability of a test compound to alter the stimulus intensity, expressed as current (mA), required to induce the presence of tonic hind limb extensor convulsions, is assessed in the MEST. The outcome of the presence (+) or absence (0) of tonic hind limb extensor convulsions observed from a current to produce tonic hind limb extension in 50% of animals in the treatment group (CC.sub.50) determines the seizure threshold for the treatment group and the effects were then compared to the CC.sub.50 of the vehicle control group.

Methods

(45) Study Details:

(46) Naïve mice were acclimatised to the procedure room in their home cages for up to 7 days, with food and water available ad libitum.

(47) All animals were weighed at the beginning of the study and randomly assigned to treatment groups based on a mean distribution of body weight across groups. All animals were dosed at 10 mL/kg via intraperitoneal (i.p) injection, with either vehicle, test compound at 3, 10 or 30 mg/kg or diazepam at 2.5 mg/kg.

(48) Animals were individually assessed for the production of a tonic hind limb extensor convulsion at 30 min post-dose for vehicle, 30, 15 and 60 min post-dose for 6-OH CBD at 3, 10 and 30 mg/kg respectively, and 30 min post-dose for diazepam, from a single electroshock.

(49) The first animal within a treatment group was given a shock at the expected or estimated CC.sub.50 current. For subsequent animals, the current was lowered or raised depending on the convulsions outcome from the preceding animal.

(50) Data generated from each treatment group were used to calculate the CC.sub.50±SEM values for the treatment group.

(51) Test Compounds:

(52) Vehicle: (5% ethanol, 5% solutol, 90% Saline) was prepared as follows: 2 mL of ethanol, 2 mL of solutol were warmed to 60° C., in 36 mL of saline (1:1:18).

(53) Positive control: diazepam was used at 2.5 mg/kg.

(54) The test compound, alpha 6-OH CBD was prepared according to the method described in Example 1. 6-OH CBD was administered at 3, 10 and 30 mg/kg (i.p.) in a 1:1:18 ethanol:solutol:0.9% saline formulation.

(55) Sample Collection:

(56) Each animal was humanely killed immediately after production of a convulsion by destruction of the brain from striking the cranium, followed by the confirmation of permanent cessation of the circulation from decapitation under The Humane Killing of Animals under Schedule 1 to the Animals (Scientific Procedures) Act 1986. Terminal blood and brain collection were performed following decapitation.

(57) Blood was collected in Lithium-heparin tubes and centrifuged at 4° C. for 10 minutes at 1500×g. The resulting plasma was removed (>100 μL) and split into 2 aliquots of 0.5 mL Eppendorf tubes containing 100 μL of ascorbic acid (100 mg/mL) for stabilisation. Brains were removed, washed in saline and halved. Each half was placed into separate 2 mL screw cap cryovials, weighed and frozen on cardice.

Statistical Analysis

(58) The data for each treatment group were recorded as the number of +'s and 0's at each current level employed and this information is then used to calculate the CC_{50} value (current required for 50% of the animals to show seizure behaviour)±standard error.

(59) 6-OH CBD effects were also calculated as percentage change in CC_{50} from the vehicle control group.

(60) Significant difference between drug-treated animals and controls were assessed according to Litchfield and Wilcoxon (1949).

Results

(61) Table 2 below demonstrates the data produced in this experiment, and FIG. **1** illustrates these results.

(62) In the vehicle group, the CC_{50} value was calculated to be 24.0 mA.

(63) In the positive control diazepam (2.5 mg/kg) treated group, administered i.p. 30 minutes before the test, the CC_{50} value was 48.8 mA. This result was statistically significant ($p<0.001$) compared to the vehicle control.

(64) In the 6-OH CBD treatment groups, administered i.p. 30, 15, and 60 minutes before the test, the doses of 3, 10 and 30 mg/kg 6-OH CBD produced a statistically significant CC_{50} value compared to vehicle at all three doses of the compound.

(65) Such data are indicative that this compound will be of therapeutic benefit.

(66) TABLE-US-00003 TABLE 2 Evaluation of effect of 6-OH CBD in the MEST test

Treatment	Dose (mg/kg)	N	Pre-treatment time (mins)	CC_{50} ± SEM	% change from vehicle	Significance
Vehicle	—	12	30	24.0 ± 0.4	—	—
Diazepam	2.5	12	30	48.8 ± 1.1	103%	P < 0.001
6-OH CBD	3	12	30	30.0 ± 1.1	25%	P < 0.001
6-OH CBD	10	12	15	56.5 ± 2.1	135%	P < 0.001
6-OH CBD	30	12	60	102.5 ± 2.2	327%	P < 0.001

Conclusions

(67) 6-OH CBD produced a dose-related increase in MEST, which provides evidence that this compound exhibits anticonvulsive properties. Significant effects were observed at 3, 10, and 30 mg/kg, when compared to vehicle.

(68) These data are significant as they provide heretofore unknown evidence that this cannabinoid may be of therapeutic value.

Example 4: Pharmacokinetics of 6-Hydroxy Cannabidiol (6-OH CBD)

(69) The objective of this study was to determine brain and plasma pharmacokinetic parameters of

6-OH CBD following a single intravenous or intraperitoneal administration of 6-OH CBD to the mouse; and to determine brain: plasma concentration ratios for 6-OH CBD.

Methods

(70) Ninety-nine male mice each received a single intravenous or intraperitoneal dose of 6-OH CBD, as detailed below in Table 3.

(71) TABLE-US-00004 TABLE 3 Details of dosing Dose level Number of Dose route (mg/kg) animals intravenous 1 27 intraperitoneal 3 27 intraperitoneal 10 27 intraperitoneal 30 27

(72) For each formulation, 6-OH CBD was formulated at the required concentration in ethanol: Kolliphor EL (Cremophor EL): 0.9% (w/v) Saline (1:1:18, v/v/v).

(73) Each animal received a single intravenous administration, via a tail vein, at a nominal dose volume of 2 mL/kg or a single intraperitoneal administration at a nominal dose volume of 5 mL/kg.

(74) Following dosing, terminal blood samples were collected from each animal via cardiac puncture, and brains were excised, at each of the following time points: Intravenous groups: 7, 15 and 30 minutes, 1, 2, 4, 8, 12 and 24 hours; Intraperitoneal groups: 15 and 30 minutes, 1, 2, 4, 8, 12 and 24 hours.

(75) Blood was collected into tubes containing lithium heparin anticoagulant and centrifuged to prepare plasma. Brain samples were frozen on dry ice, then weighed and stored deep frozen prior to bioanalysis. The remaining carcasses were discarded. Plasma was stabilised with an equal volume of ascorbic acid solution, then stored deep frozen prior to bioanalysis.

(76) Stabilised plasma samples were analysed to determine the concentrations of 6-OH CBD, using qualified LC-MS/MS methods. The results of these analyses were evaluated to determine non-compartmental pharmacokinetic parameters.

Results

(77) Tables 4 and 5 demonstrate the results obtained in this study, and FIG. **2** illustrates the results. The following parameters were determined:

(78) The following parameters were determined: C_{max} Maximum concentration observed. T_{max} Time of maximum observed concentration. AUC_{0-t} Area under the concentration-time curve from hour 0 to the last quantifiable concentration, estimated by the linear trapezoidal rule. AUC_{0-24} Area under the concentration-time curve from hour 0 to hour 24, estimated using the linear trapezoidal rule. $t_{1/2}$ Elimination half-life, determined as $\ln(2)/\lambda z$. Cl Clearance, calculated (for intravenous doses only) as $Dose/AUC_{0-inf}$. Vss Volume of distribution, based on the terminal elimination phase, calculated (for intravenous doses only) as $Cl/\lambda z$. F_{abs} Absolute bioavailability of the intraperitoneal dose.

(79) TABLE-US-00005 TABLE 4 Composite pharmacokinetic parameters of 6-OH CBD in the plasma and brain following a single intravenous or intraperitoneal administration Dose Level C_{max} T_{max} AUC_{0-t} AUC_{0-24} $t_{1/2}$ F_{abs} CI Vss Matrix Treatment (mg/kg) (ng/mL) (h) (h * ng/mL) (h * ng/mL) (h) (%) (mL/min/kg) (L/kg) Plasma IV 1 775 0.117 342 343 0.451 NA 48.7 1.90 IP 3 658 0.250 533 535 0.993 52.1 NA NA IP 10 2550 0.250 2590 2600 1.08 75.8 NA NA IP 30 11000 0.250 17700 17700 0.959 173 NA NA Brain IV 1 1580 0.117 679 690 0.312 NA NA NA IP 3 851 0.500 756 768 0.569 NA NA NA IP 10 3680 0.250 3750 3940 0.706 NA NA NA IP 30 13500 1.00 25000 25000 0.919 NA NA NA

(80) TABLE-US-00006 TABLE 5 Brain: plasma ratios for 6-OH CBD C_{max} and AUC_{0-24} values following a single intraperitoneal administration of 6-OH CBD Dose Dose level Brain: Plasma Route (mg/kg) C_{max} AUC_{0-24} IV 1 2.03 2.01 IP 3 1.29 1.44 IP 10 1.45 1.52 IP 30 1.23 1.41

(81) As can be seen from Table 4, following intravenous (IV) administration of 6-OH CBD, at a dose level of 1 mg/kg, T_{max} was observed at 0.117 hours (7 minutes) post dose. After reaching C_{max}, 6-OH CBD concentrations declined, with a half-life ($t_{1/2}$) of 0.451 hours. Total plasma clearance was 48.7 mL/min/kg and the volume of distribution was 1.90 L/kg.

(82) After intraperitoneal (IP) administration at 3, 10 or 30 mg/kg, 6-OH CBD was absorbed, with

T.sub.max values of 0.250 hours (15 minutes) at each dose level. After reaching C.sub.max, plasma concentrations declined, with half-life (t.sub.1/2) values ranging between 0.993 and 1.08 hours and similar across each dose level assessed.

(83) Following IP administration, 6-OH CBD exposure in plasma (as assessed by C.sub.max and AUC.sub.0-24 values) increased with each increase in dose level between 3 and 30 mg/kg. The observed increases in exposure were greater than dose-proportional, with increases of 16.7-fold for C.sub.max and 33.2-fold for AUC.sub.0-24 for a 10-fold increase in dose level.

(84) The absolute bioavailability of 6-OH CBD following IP administration was 52.1%, 75.8% and 173%, at 3, 10 and 30 mg/kg respectively.

(85) After systemic administration, 6-OH CBD appeared in brain, with T.sub.max values of 0.117 hours after IV dosing and ranging from 0.250 to 1 hours. After reaching C.sub.max, 6-OH CBD concentrations declined, with half-life (t.sub.1/2) values of 0.312 hours following IV administration and ranging between 0.569 and 0.919 hours, with the trend to increase with increasing dose level, following IP administration.

(86) As can be seen from Table 5, following IP administration, 6-OH CBD exposure in brain (as assessed by C.sub.max and AUC.sub.0-24 values) increased with each increase in dose level between 3 and 30 mg/kg. The observed increases in exposure were greater than dose-proportional, with increases of 15.8-fold for C.sub.max and 32.6-fold for AUC.sub.0-24 for a 10-fold increase in dose level.

(87) Brain: plasma ratios for 6-OH CBD C.sub.max and AUC.sub.0-24 ranged from 1.23 to 2.03 for C.sub.max and 1.41 to 2.01 for AUC.sub.0-24. Following IP administration, the ratios for both parameters were similar across each of the dose levels assessed. However, the ratios for both parameters were higher following IV compared with IP administration.

CONCLUSION

(88) After intraperitoneal administration, 6-OH CBD was absorbed with T.sub.max values of 15 min for all dosed IP; and 7 min for 1 mg/kg IV.

(89) The results of this study provide evidence of good pharmacokinetic parameters (bioavailability, clearance etc.) for the compound 6-OH CBD.

Claims

1. A method of treating epilepsy in a subject in need thereof, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of 6-hydroxy cannabidiol (6-OH CBD) as the only active ingredient.

2. The method of claim 1, wherein the 6-OH CBD is in the form of a synthetic compound.

3. The method of claim 1, wherein the 6-OH CBD is in the form of a pure or isolated compound.

4. The method of claim 1, comprising administering a dose of 6-OH CBD that is less than 100 mg/kg/day to 1 mg/kg/day.

5. The method of claim 1, comprising administering a dose of 6-OH CBD that is less than 100 mg/kg/day.

6. The method of claim 1, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients.

7. The method of claim 1, wherein the subject is a mammal.

8. The method of claim 1, wherein the subject is a human.

9. The method of claim 1, wherein the subject is a dog.

10. The method of claim 1, comprising administering a dose of 6-OH CBD that is from 1 mg/kg/day to about 250 mg/kg/day.